We use cookies.

To make your experience the best it can be, we use cookies and similar technologies on our site. We need your permission to allow these technologies, which will maximise browsing experience. For more information on how we use cookies and how to change your cookie settings, please see our cookies and privacy policy.

X
CONTACT US

CONTACT US

Please complete this short form to get in touch with a member of our team and we will get back to you as soon as we can.

Header image for the current page Best practice article in the Journal of Pharmacy Management October 2020

Best practice article in the Journal of Pharmacy Management October 2020

Share this page

Arden & GEM’s medicines optimisation team has had an article published in the latest issue of the Journal of Pharmacy Management, covering an innovative project to accelerate the uptake of biosimilars with a high cost drugs in-reach pharmacist.

To help tackle the growing spend on medicines in hospitals, NHS England set ambitious targets to encourage hospitals to switch eligible patients from high cost biologic drugs to more affordable biosimilar drugs, with the same efficacy. The objective was to realise potential savings of £200-300m per year by 2020/21. However, the switching process was resource-hungry, requiring extensive engagement with clinicians and patients to encourage take-up of biosimilars, as well as careful monitoring of those agreeing to switch.

To reduce the burden on hospital staff and accelerate the uptake of biosimilars, NHS Arden & GEM CSU developed an innovative in-reach pharmacist model which saw a CSU pharmacist based onsite at a hospital trust, dedicated solely to delivering the biosimilar switch programme, focusing initially on adalimumab – the most commonly used biologic medicine. Working in partnership with the Trust’s rheumatology and pharmacy teams, this in-reach approach delivered cost savings of £775,000 within six months, against a total budget of £7.5 million, and saw the Trust exceed its target in switching patients from the branded adalimumab drug to the biosimilar agent.

Authored by Jas Sagoo, Medicines Optimisation Lead Pharmacist and Fozia Akhtar, Medicines Optimisation Pharmacist, the full article – covering the project’s challenges, approach and outcomes – is available here.